Regulatory comments

Comment on issues to be considered by the interagency group in the CFTC carbon market study mandated by Section 750 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act).

KAW letter to FDA requesting that the Food and Drug Administration (“FDA”) make public the data under the ADUFA data provision the amount of each antimicrobial sold or distributed for use in food-producing animals in 2009.

Comments submitted to the FDA on the Ferm Solutions, Inc. Food Additive Petition (Animal Use) for Virginiamycin, Docket No. FDA–2010–F–0510.

Joint letter by Keep Antibiotics Working coalition members to FDA regarding virginiamycin/distillers grains petition. KAW comments on the Ferm Solutions, Inc. Food Additive Petition (Animal Use) for Virginiamycin, Docket No. FDA–2010–F–0510.

Keep Antibiotics Working (KAW) and Union of Concerned Scientists (UCS) letter to FDA regarding its lack of including ABR as a strategic priority in its plan.

The climate negotiations in China where countries finished negotiating for six days (October 4–9) wrapped up just over a week ago. This was countries' last chance to reach common ground for major decisions on global warming before the U.N. Framework Convention on Climate Change (UNFCCC) holds its 16th conference of the parties (COP 16) in less than two months in Cancún, Mexico.